REG - Destiny Pharma PLC - Result of GM and Cancellation of Trading on AIM

Destiny PharmaAnnouncement

31/07/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240731:nRSe5920Ya&default-theme=true

RNS Number : 5920Y  Destiny Pharma PLC  31 July 2024

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Result of General Meeting and Cancellation of Admission to Trading on AIM

 

 

Brighton, United Kingdom - 31 July 2024 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life threatening
infections, announces that, at the general meeting of the Company held earlier
today (the "General Meeting"), all resolutions put to the Company's
shareholders ("Shareholders") were duly passed.

 

The table below sets out the details of the votes put to Shareholders:

 

 Special Resolution Number  Special Resolution Name                             Votes for                       Votes Against                     Votes Withheld*  Total Votes Cast (excl. withheld)
                            No. of shares                                                    % of shares voted  No. of shares  % of shares voted  No. of shares
 1                          Cancellation Resolution                                                                                                                41,194,114

                                                                                36,177,977   87.82%             5,016,137      12.18%             48,982
 2                          Re-registration Resolution                                                                                                             41,194,114

                                                                                36,329,435   88.19%             4,864,679      11.81%             48,982
 3                          Adoption of New Articles of Association Resolution                                                                                     41,194,114

                                                                                36,183,961   87.84%             5,010,153      12.16%             48,982

*A vote withheld is not a vote in law and is not counted in the calculation of
the proportion of votes 'For' or 'Against'

 

In accordance with the passing of Resolutions 2 and 3, the Company will
re-register as a private limited company with the name Destiny Pharma Limited
and adopt new articles of association, which is expected to take place on or
around 30 August 2024.

 

The full text of the resolutions proposed and passed at the General Meeting
can be found in the circular containing, inter alia, the Notice of General
Meeting, which was published and posted to Shareholders on 15 July 2024 and is
available on the Company's website www.destinypharma.com
(http://www.destinypharma.com) (the "Circular").

 

AIM Delisting

 

Following approval by Shareholders at the General Meeting, the admission of
the ordinary shares of 1 pence each in the capital of the Company (the
"Ordinary Shares") to trading on AIM will be cancelled (the "AIM Delisting").
The AIM Delisting is expected to take place at 7.00 a.m. on 13 August 2024
and, accordingly, the last day of dealings in Ordinary Shares on AIM is
expected to be 12 August 2024.

 

Matched Bargain Facility

 

It remains the Company's intention to provide a matched bargain facility to
assist Shareholders wishing to trade in Ordinary Shares following the AIM
Delisting. Further details with respect to the matched bargain facility, to be
provided by J P Jenkins, will be made available in due course on the Company's
website www.destinypharma.com (http://www.destinypharma.com) .

 

Capitalised terms used but not defined in this announcement shall have the
same meaning given to such terms in the Circular.

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com (mailto:destinypharma@fticonsulting.com)

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development pipeline includes
two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA
and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86YTgzNTY4M2FkNmQyNzcyNmJlNWViN2U1MzU0ZjJmN2U6NjoxYWQ4OmYzMjJhZGVkMjlkZTUxYjRlYTI3M2QxNTNjYzkyYmEzZGU0ZGNlMWEzN2E2NjE3YzA5NGFkOTRkZmRjZGUyYjc6cDpG)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMKFLBXZDLEBBK